Drug Trial Radar · NCT00910455
Study of SRX246 Capsules in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Mar 17, 2010 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
49
Actual
Start
May 2009
Primary completion
Sep 2009
Study completion Sep 2009
Sponsor
- Lead sponsor
- Azevan PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Single group
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is the first study of SRX246 in humans, and is being conducted to begin to establish a safety profile of orally administered SRX246.
Conditions
- Healthy
Interventions
SRX246Drug
single oral dose of SRX246 capsule
PlaceboDrug
Single oral dose of placebo capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess safety and tolerability of SRX246 at single doses ranging between 20 and 360 mgTime frame: 24 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Advanced Biomedical Research
Hackensack, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.